Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency

References

• Klausz K, Berger S, Lammerts van Bueren JJ, Derer S, Lohse S, Dechant M, van de Winkel JG, Peipp M, Parren PW, Valerius T. Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). Cancer Sci 2011; 102:1761-8; PMID:21718386; http://dx.doi.org/10.1111/j.1349-7006.2011.02019.x
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358:1160-74; PMID:18337605; http://dx.doi.org/10.1056/NEJMra0707704
   PubMed Web of Science ®Google Scholar
• Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 2008; 26:1742-51; PMID:18375904; http://dx.doi.org/10.1200/JCO.2007.12.1178
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787-99; PMID:12860957; http://dx.doi.org/10.1200/JCO.2003.01.504
   PubMed Web of Science ®Google Scholar
• You B, Chen EX. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab. J Clin Pharmacol 2011; 52(2):128-55; PMID:21427284; 10.1177/0091270010395940
   PubMed Web of Science ®Google Scholar
• Peipp M, Dechant M, Valerius T. Effector mechanisms of therapeutic antibodies against ErbB receptors. Curr Opin Immunol 2008; 20:436-43; PMID:18585454; http://dx.doi.org/10.1016/j.coi.2008.05.012
   PubMed Web of Science ®Google Scholar
• Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, Lammerts van Bueren JJ, Bleeker WK, Parren PW, van de Winkel JG, et al. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 2008; 68:4998-5003; PMID:18593896; http://dx.doi.org/10.1158/0008-5472.CAN-07-6226
   PubMed Web of Science ®Google Scholar
• Oppenheim DE, Spreafico R, Etuk A, Malone D, Amofah E, Pena-Murillo C, Murray T, McLaughlin L, Choi BS, Allan S, et al. Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. Br J Cancer 2014; 110:1221-7; PMID:24496456; http://dx.doi.org/10.1038/bjc.2014.35
   PubMed Web of Science ®Google Scholar
• Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PH, Derer S, Beyer T, Lohse S, Bleeker WK, Peipp M, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010; 184:512-20; PMID:19949082; http://dx.doi.org/10.4049/jimmunol.0900847
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Verploegen S, Ortiz Buijsse A, Vink T, Leusen JH, Bleeker WK, Parren PW. Crosstalk between human IgG isotypes and murine effector cells. J Immunol 2012; 189:3430-8; PMID:22956577; http://dx.doi.org/10.4049/jimmunol.1200356
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23:5235-46; PMID:16051966; http://dx.doi.org/10.1200/JCO.2005.00.6916
   PubMed Web of Science ®Google Scholar
• Lichtenberger BM, Gerber PA, Holcmann M, Buhren BA, Amberg N, Smolle V, Schrumpf H, Boelke E, Ansari P, Mackenzie C, et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med 2013; 5:199ra11; PMID:23966300; http://dx.doi.org/10.1126/scitranslmed.3005886
   PubMed Web of Science ®Google Scholar
• Capdevila J, Elez E, Macarulla T, Ramos FJ, Ruiz-Echarri M, Tabernero J. Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat Rev 2009; 35:354-63; PMID:19269105; http://dx.doi.org/10.1016/j.ctrv.2009.02.001
   PubMed Web of Science ®Google Scholar
• Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999; 59:1236-43; PMID:10096554
   PubMed Web of Science ®Google Scholar
• Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 2007; 25:1134-43; PMID:17921999; http://dx.doi.org/10.1038/nbt1337
   PubMed Web of Science ®Google Scholar
• Hoy SM, Wagstaff AJ. Panitumumab: in the treatment of metastatic colorectal cancer. Drugs 2006; 66:2005-14; discussion 15-6; PMID:17100412; http://dx.doi.org/10.2165/00003495-200666150-00011
   PubMed Web of Science ®Google Scholar
• Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012; 18:221-3; PMID:22270724; http://dx.doi.org/10.1038/nm.2609
   PubMed Web of Science ®Google Scholar
• Voigt M, Braig F, Gothel M, Schulte A, Lamszus K, Bokemeyer C, Binder M. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia 2012; 14:1023-31; PMID:23226096
   PubMed Web of Science ®Google Scholar
• Kasper S, Breitenbuecher F, Reis H, Brandau S, Worm K, Kohler J, Paul A, Trarbach T, Schmid KW, Schuler M. Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade. Oncogene 2012; 32(23):2873-81; PMID:22797062; http://dx.doi.org/10.1038/onc.2012.302
   PubMed Web of Science ®Google Scholar
• Kubach J, Hubo M, Amendt C, Stroh C, Jonuleit H. IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity. Int J Cancer 2014; 136(4):821-30; PMID:24947844; http://dx.doi.org/10.1002/ijc.29037
   PubMed Web of Science ®Google Scholar
• Laux I, Jain A, Singh S, Agus DB. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer 2006; 94:85-92; PMID:16306877; http://dx.doi.org/10.1038/sj.bjc.6602875
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R, Haas N, Lockbaum P, Li YP, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22:3003-15; PMID:15210739; http://dx.doi.org/10.1200/JCO.2004.11.061
   PubMed Web of Science ®Google Scholar
• Miettinen PJ, Berger JE, Meneses J, Phung Y, Pedersen RA, Werb Z, Derynck R. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995; 376:337-41; PMID:7630400; http://dx.doi.org/10.1038/376337a0
   PubMed Web of Science ®Google Scholar
• Desnoyers LR, Vasiljeva O, Richardson JH, Yang A, Menendez EE, Liang TW, Wong C, Bessette PH, Kamath K, Moore SJ, et al. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci Transl Med 2013; 5:207ra144; PMID:24132639; http://dx.doi.org/10.1126/scitranslmed.3006682
   PubMed Web of Science ®Google Scholar
• Erster O, Thomas JM, Hamzah J, Jabaiah AM, Getz JA, Schoep TD, Hall SS, Ruoslahti E, Daugherty PS. Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases. J Control Release 2012; 161:804-12; PMID:22634092; http://dx.doi.org/10.1016/j.jconrel.2012.05.035
   PubMed Web of Science ®Google Scholar
• Dillon TM, Ricci MS, Vezina C, Flynn GC, Liu YD, Rehder DS, Plant M, Henkle B, Li Y, Deechongkit S, et al. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 2008; 283:16206-15; PMID:18339626; http://dx.doi.org/10.1074/jbc.M709988200
   PubMed Web of Science ®Google Scholar
• Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, et al. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res 2013; 19:1126-38; PMID:23209031; http://dx.doi.org/10.1158/1078-0432.CCR-12-0989
   PubMed Web of Science ®Google Scholar
• Chung S, Quarmby V, Gao X, Ying Y, Lin L, Reed C, Fong C, Lau W, Qiu ZJ, Shen A, et al. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcgamma receptor binding and antibody-dependent cell-mediated cytotoxicity activities. MAbs 2012; 4:326-40; PMID:22531441; http://dx.doi.org/10.4161/mabs.19941
   PubMed Web of Science ®Google Scholar
• Parekh BS, Berger E, Sibley S, Cahya S, Xiao L, LaCerte MA, Vaillancourt P, Wooden S, Gately D. Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay. MAbs 2012; 4:310-8; PMID:22531445; http://dx.doi.org/10.4161/mabs.19873
   PubMed Web of Science ®Google Scholar
• Tada M, Ishii-Watabe A, Suzuki T, Kawasaki N. Development of a cell-based assay measuring the activation of FcgammaRIIa for the characterization of therapeutic monoclonal antibodies. PLoS One 2014; 9:e95787; PMID:24752341; http://dx.doi.org/10.1371/journal.pone.0095787
   PubMed Web of Science ®Google Scholar
• Ulisse S, Baldini E, Sorrenti S, D'Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 2009; 9:32-71; PMID:19200050; http://dx.doi.org/10.2174/156800909787314002
   PubMed Web of Science ®Google Scholar
• Gerspach J, Nemeth J, Munkel S, Wajant H, Pfizenmaier K. Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface. Cancer Immunol Immunother 2006; 55:1590-600; PMID:16636812; http://dx.doi.org/10.1007/s00262-006-0162-6
   PubMed Web of Science ®Google Scholar
• Zuluaga MF, Sekkat N, Gabriel D, van den Bergh H, Lange N. Selective photodetection and photodynamic therapy for prostate cancer through targeting of proteolytic activity. Mol Cancer Ther 2013; 12:306-13; PMID:23270928; http://dx.doi.org/10.1158/1535-7163.MCT-12-0780
   PubMed Web of Science ®Google Scholar
• Corti A, Nolli ML, Soffientini A, Cassani G. Purification and characterization of single-chain urokinase-type plasminogen activator (pro-urokinase) from human A431 cells. Thromb Haemost 1986; 56:219-24; PMID:3101222
   PubMed Web of Science ®Google Scholar
• Stoppelli MP, Tacchetti C, Cubellis MV, Corti A, Hearing VJ, Cassani G, Appella E, Blasi F. Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell 1986; 45:675-84; PMID:3011276; http://dx.doi.org/10.1016/0092-8674(86)90782-8
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-34; PMID:18316791; http://dx.doi.org/10.1200/JCO.2007.14.7116
   PubMed Web of Science ®Google Scholar
• Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:3992-5; PMID:16618717; http://dx.doi.org/10.1158/0008-5472.CAN-06-0191
   PubMed Web of Science ®Google Scholar
• Saif MW, Kaley K, Chu E, Copur MS. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clin Colorectal Cancer 2010; 9:315-8; PMID:21208847; http://dx.doi.org/10.3816/CCC.2010.n.046
   PubMed Web of Science ®Google Scholar
• Natsume A, In M, Takamura H, Nakagawa T, Shimizu Y, Kitajima K, Wakitani M, Ohta S, Satoh M, Shitara K, et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res 2008; 68:3863-72; PMID:18483271; http://dx.doi.org/10.1158/0008-5472.CAN-07-6297
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006; 177:362-71; PMID:16785532; http://dx.doi.org/10.4049/jimmunol.177.1.362
   PubMed Web of Science ®Google Scholar
• Mascia F, Lam G, Keith C, Garber C, Steinberg SM, Kohn E, Yuspa SH. Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy. Sci Transl Med 2013; 5:199ra10; PMID:23966299; http://dx.doi.org/10.1126/scitranslmed.3005773
   PubMedGoogle Scholar
• Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, Arvind AS. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 2009; 1:41-8; PMID:20046573; http://dx.doi.org/10.4161/mabs.1.1.7509
   PubMed Web of Science ®Google Scholar
• Allan DG. Nimotuzumab: evidence of clinical benefit without rash. Oncologist 2005; 10:760-1; PMID:16249358; http://dx.doi.org/10.1634/theoncologist.10-9-760
   PubMed Web of Science ®Google Scholar
• Shin TH, Sung ES, Kim YJ, Kim KS, Kim SH, Kim SK, Lee YD, Kim YS. Enhancement of the tumor penetration of monoclonal antibody by fusion of a neuropilin-targeting peptide improves the antitumor efficacy. Mol Cancer Ther 2014; 13:651-61; PMID:24435448; http://dx.doi.org/10.1158/1535-7163.MCT-13-0748
   PubMed Web of Science ®Google Scholar